1. Market Research
  2. > Emisphere Technologies, Inc. – Product Pipeline Review – 2013

Emisphere Technologies, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 48 pages

Emisphere Technologies, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Emisphere Technologies, Inc. - Product Pipeline Review - 2013” provides data on the Emisphere Technologies, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Emisphere Technologies, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Emisphere Technologies, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Emisphere Technologies, Inc. - Brief Emisphere Technologies, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Emisphere Technologies, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Emisphere Technologies, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Emisphere Technologies, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Emisphere Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Emisphere Technologies, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Emisphere Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Emisphere Technologies, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Emisphere Technologies, Inc. and identify potential opportunities in those areas.

Table Of Contents

Emisphere Technologies, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Emisphere Technologies, Inc. Snapshot 5
Emisphere Technologies, Inc. Overview 5
Key Information 5
Key Facts 5
Emisphere Technologies, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Emisphere Technologies, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Emisphere Technologies, Inc. - Pipeline Products Glance 10
Emisphere Technologies, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Emisphere Technologies, Inc. - Drug Profiles 12
acyclovir 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
ardeparin sodium 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Oral Eligen B12 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
PYY3-36 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
somatropin 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Emisphere Technologies, Inc. - Pipeline Products by Route of Administration 18
Emisphere Technologies, Inc. - Pipeline Products By Mechanism of Action 19
Emisphere Technologies, Inc. - Recent Pipeline Updates 20
Emisphere Technologies, Inc. - Company Statement 21
Emisphere Technologies, Inc. - Locations And Subsidiaries 25
Head Office 25
Emisphere Technologies, Inc., Recent Developments 26
Emisphere Technologies, Inc.- Press Release 26
Oct 22, 2010: Emisphere Reports Notification Of Top Level Results On Phase III Study Of Oral Calcitonin In Osteoarthritis Patients 26
Jul 23, 2010: Emisphere Provides Update On Osteoarthritis Phase III Study With Oral Calcitonin 26
Jul 17, 2010: Emisphere Technologies Provides Update On High Dose Oral Eligen B12 27
Financial Deals Landscape 28
Emisphere Technologies, Inc., Deals Summary 28
Emisphere Technologies, Inc., Pharmaceuticals and Healthcare, Deal Details 29
Partnerships 29
Emisphere Technologies Enters Into Research Collaboration With Alchemia 29
Emisphere Technologies Enters Into Co-Development Agreement With AAIPharma 30
Licensing Agreements 31
Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk 31
Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk For GLP-1 Receptor 32
Equity Offering 33
Emisphere Technologies Completes Private Placement Of Units For $3.75 Million 33
Emisphere Technologies Issues Units To MHR In Private Placement For $3.75 Million 35
Emisphere Technologies Completes Private Placement Of $3.5 Million 37
Emisphere Technologies Completes Private Placement Of $3.5 Million 39
Emisphere Technologies Completes Registered Direct Offering Of $4 Million 41
Emisphere Technologies Completes Private Placement Of $4 Million 43
Emisphere Technologies Completes Registered Direct Offering Of $7.6 Million 45
Debt Offering 46
Emisphere Technologies Completes Convertible Notes Offering For $1.27 Million 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48



List of Tables

Emisphere Technologies, Inc., Key Information 5
Emisphere Technologies, Inc., Key Facts 5
Emisphere Technologies, Inc. - Pipeline by Indication, 2013 7
Emisphere Technologies, Inc. - Pipeline by Stage of Development, 2013 8
Emisphere Technologies, Inc. - Monotherapy Products in Pipeline, 2013 9
Emisphere Technologies, Inc. - Phase II, 2013 10
Emisphere Technologies, Inc. - Phase I, 2013 11
Emisphere Technologies, Inc. - Pipeline By Route of Administration, 2013 18
Emisphere Technologies, Inc. - Pipeline Products By Mechanism of Action, 2013 19
Emisphere Technologies, Inc. - Recent Pipeline Updates, 2013 20
Emisphere Technologies, Inc., Deals Summary 28
Emisphere Technologies Enters Into Research Collaboration With Alchemia 29
Emisphere Technologies Enters Into Co-Development Agreement With AAIPharma 30
Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk 31
Emisphere Technologies Enters Into Licensing Agreement With Novo Nordisk For GLP-1 Receptor 32
Emisphere Technologies Completes Private Placement Of Units For $3.75 Million 33
Emisphere Technologies Issues Units To MHR In Private Placement For $3.75 Million 35
Emisphere Technologies Completes Private Placement Of $3.5 Million 37
Emisphere Technologies Completes Private Placement Of $3.5 Million 39
Emisphere Technologies Completes Registered Direct Offering Of $4 Million 41
Emisphere Technologies Completes Private Placement Of $4 Million 43
Emisphere Technologies Completes Registered Direct Offering Of $7.6 Million 45
Emisphere Technologies Completes Convertible Notes Offering For $1.27 Million 46



List of Figures

Emisphere Technologies, Inc. - Pipeline by Indication, 2013 7
Emisphere Technologies, Inc. - Pipeline by Stage of Development, 2013 8
Emisphere Technologies, Inc. - Monotherapy Products in Pipeline, 2013 9
Emisphere Technologies, Inc. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.